Peter Arduini - Bristol-Myers Squibb Independent Director
Director
Mr. Peter J. Arduini serves as Independent Director of the Company effective April 1, 2016. Mr. Arduini was President and Chief Executive Officer at Integra LifeSciences Holdings Corporationrationration, a global medical technology company since January 2012 and currently serves as a member of Integra Board of Directors. He served as President and Chief Operating Officer of Integra from November 2010 to January 2012. Before joining Integra, Mr. Arduini was Corporationrationrate Vice President and President of Medication Delivery, Baxter Healthcare from 2005 until 2010. Prior to joining Baxter, he worked for General Electric Healthcare, where he spent much of his 15 years in a variety of management roles for domestic and global businesses, culminating in leading the global functional imaging business. Mr. Arduini also serves on the Board of Directors of ADVAMED, the Board of Directors of MDIC, and the Board of Directors of the National Italian American Foundation. He also serves on the Board of Trustees of Susquehanna University. since 2016.
Age | 53 |
Tenure | 8 years |
Phone | 212-546-4000 |
Web | http://www.bms.com |
Similar Executives
Showing other executives | DIRECTOR Age | ||
Toshiaki Tojo | Daiichi Sankyo | 61 | |
Pius Baschera | Roche Holding AG | 65 | |
Marcus Wallenberg | AstraZeneca PLC | 62 | |
Claudie Haignere | Sanofi ADR | 60 | |
Naoki Okamura | Astellas Pharma | N/A | |
Beatrice Mauro | Roche Holding Ltd | 49 | |
Marc Dunoyer | AstraZeneca PLC ADR | 72 | |
Simon Dingemans | GlaxoSmithKline PLC ADR | 53 | |
Sherilyn McCoy | AstraZeneca PLC ADR | 60 | |
Akihiko Iwai | Astellas Pharma | N/A | |
Philip Broadley | AstraZeneca PLC | 52 | |
Elizabeth Doherty | Novartis AG | 61 | |
Akira Kamimura | Astellas Pharma | N/A | |
Kazuo Sato | Daiichi Sankyo | N/A | |
Rudolph Markham | AstraZeneca PLC ADR | 72 | |
Stacey Cartwright | GlaxoSmithKline PLC ADR | 51 | |
Kunio Ishihara | Daiichi Sankyo | 70 | |
Chikashi Takeda | Astellas Pharma | N/A | |
Hisanori Takanashi | Chugai Pharmaceutical Co | N/A | |
Koichi Nishikawa | Chugai Pharmaceutical Co | N/A | |
Yutaka Kase | Astellas Pharma | 68 |
Bristol Myers Squibb Leadership Team
Elected by the shareholders, the Bristol-Myers Squibb's board of directors comprises two types of representatives: Bristol-Myers Squibb inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bristol-Myers. The board's role is to monitor Bristol-Myers Squibb's management team and ensure that shareholders' interests are well served. Bristol-Myers Squibb's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bristol-Myers Squibb's outside directors are responsible for providing unbiased perspectives on the board's policies.
Ann Powell, Chief Human Resource Officer, Senior Vice President | ||
Togo West, Independent Director | ||
Karen Vousden, Director | ||
Adam Dubow, Senior Vice President Chief Compliance Officer and Ethics Officer | ||
Alan Lacy, Independent Director | ||
Robert Bertolini, Independent Director | ||
Jose Baselga, Independent Director | ||
Charles Bancroft, CFO, Executive Vice President | ||
Gerald Storch, Independent Director | ||
Louis Schmukler, President - Global Manufacturing and Supply | ||
Michael Grobstein, Independent Director | ||
Christopher Boerner, Executive Vice President and Chief Commercial Officer | ||
John Elicker, Senior Vice President - Public Affairs and Investor Relations | ||
Anne Nielsen, Senior Vice President Chief Compliance and Ethics Officer | ||
Karen Santiago, Senior Vice President Controller | ||
Giovanni Caforio, COO, Director | ||
Vicki Sato, Independent Director | ||
Emmanuel Blin, Senior Vice President Chief Strategy Officer | ||
Joseph Caldarella, Senior Vice President Corporate Controller | ||
Laurie Glimcher, Independent Director | ||
Murdo Gordon, Executive Vice President Chief Commercial Officer | ||
Lamberto Andreotti, CEO, Director | ||
Thomas Lynch, Independent Director | ||
Dinesh Paliwal, Independent Director | ||
Lewis Campbell, Independent Director | ||
Theodore Samuels, Independent Director | ||
Samuel Moed, Senior Vice President - Strategic Planning and Analysis | ||
Matthew Emmens, Independent Director | ||
Ann Judge, Senior Vice President - Global Human Resources | ||
Sandra Leung, General Counsel, Corporate Secretary | ||
Paul Autenried, Senior Vice President - Enterprise Services, CIO | ||
Francis Cuss, Executive Vice President Chief Scientific Officer | ||
Paul Biondi, Senior Vice President Head - Business Development | ||
Peter Arduini, Independent Director |
Bristol-Myers Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Bristol-Myers Squibb a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Revenue | 46.38 B | |||
EBITDA | 20.1 B | |||
Net Income | 7.01 B | |||
Cash And Equivalents | 6.07 B | |||
Cash Per Share | 3.72 X | |||
Total Debt | 39.6 B | |||
Debt To Equity | 59.40 % | |||
Current Ratio | 1.40 X | |||
Book Value Per Share | 7.55 X | |||
Cash Flow From Operations | 16.21 B |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Other Consideration for investing in Bristol-Myers Pink Sheet
If you are still planning to invest in Bristol Myers Squibb check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bristol-Myers Squibb's history and understand the potential risks before investing.
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Transaction History View history of all your transactions and understand their impact on performance | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |